CGRP antagonists are a class of targeted migraine therapies that block calcitonin gene-related peptide, a key driver of migraine attacks. Available as monoclonal antibodies for prevention and oral small-molecule gepants for both acute and preventive treatment, these therapies have transformed migraine care by offering better tolerability and lower discontinuation rates than older broad-spectrum drugs. The market is expanding rapidly, driven by the rising burden of migraine, expanded reimbursement, and the ongoing shift away from older therapies.
According to recent market analysis, the global CGRP inhibitor market was valued at approximately USD 6.20 billion in 2025 and is projected to grow at a CAGR of 11.4% through 2035 . Monoclonal antibodies account for the largest revenue share, reflecting their role in establishing the category and their continued dominance in chronic migraine prevention .
Rising Migraine Burden and Diagnosis Rates
The primary driver is the increasing recognition of migraine as a disabling neurological condition. The World Health Organization identifies migraine among the leading causes of disability in adults under 50, and neurology associations in North America and Europe have expanded screening guidance for chronic migraine patients who fail conventional therapies . Higher diagnosis rates translate directly into larger prescription volumes.
Shift Away from Older Therapies
A second driver is therapeutic substitution. CGRP antagonists offer improved tolerability and lower discontinuation rates compared with beta blockers, anticonvulsants, and triptans, making them an attractive first-line option for many patients . As payers expand coverage, this substitution accelerates.
People Also Ask
What is the market size of CGRP antagonists?
The CGRP inhibitor market was valued at approximately USD 6.20 billion in 2025 and is projected to grow at a CAGR of 11.4% through 2035.
What are the two main classes of CGRP antagonists?
The two classes are monoclonal antibodies (injectable, for prevention) and gepants (oral small molecules, for acute and preventive treatment).
Regional dynamics further shape the market. North America leads on the strength of reimbursement and specialist infrastructure, while Europe is the second-largest market and Asia-Pacific is the fastest-growing, driven by improving neurology access and rising healthcare expenditure .
Tags: #CGRPAntagonists #MigraineTreatment #MonoclonalAntibodies #Gepants #Neurology